Klotho Neurosciences, Inc. (KLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has a cash flow conversion efficiency ratio of -0.110x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.09 Million) by net assets ($9.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KLTO company net worth for the company's overall valuation and market capitalisation.
Klotho Neurosciences, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Klotho Neurosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their cash flow conversion efficiency. See KLTO operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nam Hwa Construction Co.Ltd
KQ:091590
|
-0.002x |
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
0.000x |
|
Logan Ridge Finance Corp
NASDAQ:LRFC
|
-0.015x |
|
Krungdhep Sophon Public Company Limited
BK:KWC
|
0.046x |
|
EgnsINVEST Ejendomme Tyskland A/S
CO:EGNETY
|
0.003x |
|
Lunnon Metals Ltd
AU:LM8
|
-0.119x |
|
GAMING INNOVATION DL 1
F:GI11
|
-0.578x |
|
Hotel Sahid Jaya Tbk
JK:SHID
|
0.005x |
Annual Cash Flow Conversion Efficiency for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Klotho Neurosciences, Inc. from 2021 to 2024. View current stock price of Klotho Neurosciences, Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.19 Million | $-2.95 Million | -2.486x | -217.99% |
| 2023-12-31 | $571.72K | $-446.92K | -0.782x | -53.74% |
| 2022-12-31 | $1.18 Million | $-599.57K | -0.508x | -83.75% |
| 2021-12-31 | $1.03 Million | $-284.02K | -0.277x | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more